Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

NCT00991211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

549

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin Lymphomas
Follicular Lymphomas
Immunocytomas
Lymphocytic Lymphomas
Marginal Zone Lymphomas

Interventions

DRUG: Bendamustine
DRUG: Standard chemotherapy CHOP + Ritiximab

Sponsor

University of Giessen